BR0317611A - Métodos para produção de formulações farmacêuticas que compreendem micropartìculas aglomeradas - Google Patents

Métodos para produção de formulações farmacêuticas que compreendem micropartìculas aglomeradas

Info

Publication number
BR0317611A
BR0317611A BR0317611-8A BR0317611A BR0317611A BR 0317611 A BR0317611 A BR 0317611A BR 0317611 A BR0317611 A BR 0317611A BR 0317611 A BR0317611 A BR 0317611A
Authority
BR
Brazil
Prior art keywords
microparticles
methods
dry powder
formulations
agglomerated
Prior art date
Application number
BR0317611-8A
Other languages
English (en)
Inventor
Donald E Chickering Iii
Shaina Reese
Sridhar Narasimhan
Julie A Straub
Howard Bernstein
David Altreuter
Eric K Huang
Original Assignee
Acusphere Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acusphere Inc filed Critical Acusphere Inc
Publication of BR0317611A publication Critical patent/BR0317611A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D1/00—Evaporating
    • B01D1/16—Evaporating by spraying
    • B01D1/18—Evaporating by spraying to obtain dry solids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
    • B01J2/04—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a gaseous medium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Abstract

"MéTODOS PARA PRODUçãO DE FORMULAçõES FARMACêUTICAS QUE COMPREENDEM MICROPARTìCULAS AGLOMERADAS". São fornecidos métodos para produção de formulação farmacêutica de mistura em pó seco que compreendem (i) formação de micropartículas que compreendem um agente farmacêutico; (ii ) o fornecimento de pelo menos um excipiente na forma de partículas tendo um diâmetro médio de volume que é maior que o diâmetro médio de volume das micropartículas; (iii) mistura das micropartículas com o excipiente para formar uma mistura em pó; e (iv) moagem em jato da mistura em pó para desaglomerar pelo menos uma porção de quaisquer das micropartículas que se aglomeraram, embora mantenha substancialmente o tamanho e morfologia das micropartículas individuais. A moagem em jato pode eliminar de forma vantajosa a necessidade por processos de desaglomeração úmidos mais complicados, pode diminuir os níveis de umidade residual e de solvente nas micropartículas (que leva a melhor estabilidade e propriedades de manuseio para formulações em pó seco) , e pode melhorar a capacidade de umedecimento, capacidade de suspensão, e uniformidade de conteúdo de formulações de mistura em pó seco.
BR0317611-8A 2002-12-19 2003-11-20 Métodos para produção de formulações farmacêuticas que compreendem micropartìculas aglomeradas BR0317611A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/324,558 US20040121003A1 (en) 2002-12-19 2002-12-19 Methods for making pharmaceutical formulations comprising deagglomerated microparticles
PCT/US2003/037100 WO2004060344A2 (en) 2002-12-19 2003-11-20 Methods for making pharmaceutical formulations comprising deagglomerated microparticles

Publications (1)

Publication Number Publication Date
BR0317611A true BR0317611A (pt) 2005-11-29

Family

ID=32593480

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317611-8A BR0317611A (pt) 2002-12-19 2003-11-20 Métodos para produção de formulações farmacêuticas que compreendem micropartìculas aglomeradas

Country Status (11)

Country Link
US (4) US20040121003A1 (pt)
EP (1) EP1575560A2 (pt)
JP (1) JP2006514044A (pt)
KR (1) KR20050088201A (pt)
CN (1) CN1726009A (pt)
AU (1) AU2003295698A1 (pt)
BR (1) BR0317611A (pt)
CA (1) CA2511313A1 (pt)
RU (1) RU2005122656A (pt)
WO (1) WO2004060344A2 (pt)
ZA (1) ZA200504213B (pt)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
EP1175205B1 (en) * 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
EP2085072A1 (en) * 2002-03-26 2009-08-05 Teva Pharmaceutical Industries Ltd. Drug microparticles
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
WO2004030659A1 (en) * 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040208932A1 (en) * 2003-04-17 2004-10-21 Ramachandran Thembalath Stabilized paroxetine hydrochloride formulation
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP4996249B2 (ja) * 2003-08-29 2012-08-08 ベロクシス ファーマシューティカルズ エー／エス タクロリムスを含む改質放出組成物
US20070190129A1 (en) * 2003-09-02 2007-08-16 Pfizer Inc. Sustained release dosage forms of ziprasidone
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
SG146638A1 (en) 2003-09-19 2008-10-30 Drugtech Corp Pharmaceutical delivery system
CN1856296A (zh) * 2003-09-30 2006-11-01 阿库斯菲尔公司 可注射的、口服、或局部用缓释药物制剂
WO2005053640A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
ES2600577T3 (es) * 2003-12-04 2017-02-09 Bend Research, Inc. Procedimiento de pulverización-solidificación que usa un extrusor para preparar composiciones en multipartículas de fármacos cristalinos
BRPI0416534A (pt) 2003-12-04 2007-01-09 Pfizer Prod Inc composições multiparticuladas com estabilidade melhorada
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
CA2547774A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Method for making pharmaceutical multiparticulates
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
CA2488981C (en) * 2003-12-15 2008-06-17 Rohm And Haas Company Oil absorbing composition and process
FR2868079B1 (fr) * 2004-03-29 2007-06-08 Seppic Sa Tensioactifs sous forme de poudre utilisables dans des comprimes ou des gelules procede de preparation et compositions les contenant
WO2005123086A2 (en) * 2004-06-11 2005-12-29 Dr. Reddy's Laboratories Ltd. Ziprasidone dosage form
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
JP2008511637A (ja) 2004-08-27 2008-04-17 ザ ダウ ケミカル カンパニー 致命的な感染症を治療する薬剤組成物の増強された供給
GB0501835D0 (en) * 2005-01-28 2005-03-09 Unilever Plc Improvements relating to spray dried compositions
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
CN101160118A (zh) * 2005-02-24 2008-04-09 依兰药物国际有限公司 多西紫杉醇或其类似物的纳米微粒制剂
WO2006095888A2 (en) * 2005-03-08 2006-09-14 Sumitomo Chemical Company, Limited Process for producing a mixture of particles
DE102005011786A1 (de) * 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
CA2603189A1 (en) * 2005-04-13 2006-10-19 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
BRPI0609299A2 (pt) * 2005-04-13 2010-03-23 Pfizer Prod Inc formulaÇÕes de depàsito injetÁveis e mÉtodos para proporcionar liberaÇço sustentada de composiÇÕes de nanopartÍculas
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
US10532028B2 (en) * 2005-07-28 2020-01-14 Isp Investments Llc Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
US7758778B2 (en) * 2005-09-07 2010-07-20 Southwest Research Institute Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US7261529B2 (en) * 2005-09-07 2007-08-28 Southwest Research Institute Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US9693967B2 (en) * 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
WO2013059629A1 (en) 2011-10-21 2013-04-25 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US9877921B2 (en) 2005-09-09 2018-01-30 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US20160045457A1 (en) * 2005-09-09 2016-02-18 Ousama Rachid Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine
JP5264492B2 (ja) * 2005-10-25 2013-08-14 エボニック デグサ ゲーエムベーハー 超分岐ポリマーを含有する調製物
US20070104763A1 (en) * 2005-11-10 2007-05-10 Navinta Llc Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making
US9034381B2 (en) * 2005-11-10 2015-05-19 Alphapharm Pty Ltd Process to control particle size
US8497258B2 (en) * 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) * 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
CN101309669A (zh) * 2005-11-15 2008-11-19 巴克斯特国际公司 脂氧合酶抑制剂的组合物
GB0524194D0 (en) * 2005-11-28 2006-01-04 Univ Aston Respirable powders
US20070128282A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
US20070128280A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
WO2007070852A2 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for parenteral administration
EP1978933A2 (en) * 2005-12-15 2008-10-15 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
WO2007070851A2 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
CA2635986A1 (en) * 2006-01-05 2007-07-12 Drugtech Corporation Composition and method of use thereof
WO2007100614A2 (en) * 2006-02-24 2007-09-07 Scidose, Llc STABLE NON-CRYSTALLINE FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITOR
US20080166411A1 (en) * 2006-04-10 2008-07-10 Pfizer Inc Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles
US20080187487A1 (en) * 2006-05-03 2008-08-07 Gustavo Larsen Methods for producing multilayered particles, fibers and sprays and methods for administering the same
KR100722607B1 (ko) * 2006-05-11 2007-05-28 주식회사 펩트론 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법
AU2007264418B2 (en) 2006-06-30 2012-05-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
AU2007272501A1 (en) * 2006-07-12 2008-01-17 Elan Pharma International Limited Nanoparticulate formulations of modafinil
KR100767349B1 (ko) 2006-08-01 2007-10-17 삼천당제약주식회사 페노피브레이트를 함유하는 경구용 약제 조성물 및 그의제조방법
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
JP5373618B2 (ja) * 2006-11-02 2013-12-18 オムリクス バイオファーマシューティカルズ リミテッド 微粒化方法
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
WO2008080037A2 (en) * 2006-12-21 2008-07-03 Isp Investments Inc. Carotenoids of enhanced bioavailability
WO2008092057A2 (en) * 2007-01-26 2008-07-31 Isp Investments Inc. Formulation process method to produce spray dried products
WO2008092046A2 (en) * 2007-01-26 2008-07-31 Isp Investments Inc. Amorphous oxcarbazepine and the production thereof
JP5484041B2 (ja) * 2007-02-23 2014-05-07 学校法人関西学院 蛋白質結晶化剤および蛋白質結晶化剤を用いた蛋白質結晶化方法
EP1982698A1 (de) * 2007-04-18 2008-10-22 Evonik Degussa GmbH Präparate zur gesteuerten Freisetzung von bioaktiven Naturstoffen
US8173169B2 (en) * 2007-07-11 2012-05-08 Hikma Pharmaceuticals Formulation and process for the preparation of modafinil
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
SI2197429T1 (sl) 2007-09-03 2016-09-30 Nanotherapeutics, Inc. Sestavki iz delcev za vnos slabo topnih zdravil
US8221744B2 (en) * 2007-09-19 2012-07-17 Abbott Cardiovascular Systems Inc. Cytocompatible alginate gels
EP2197416A1 (en) * 2007-10-09 2010-06-23 Novartis Ag Pharmaceutical formulation of valsartan
US20110092598A1 (en) * 2007-10-10 2011-04-21 Nandu Deorkar Driectly Compressible High Functionality Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
US20090143343A1 (en) * 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090149433A1 (en) 2007-11-13 2009-06-11 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US8124601B2 (en) * 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
WO2009085952A1 (en) 2007-12-20 2009-07-09 Brookwood Pharmaceuticals, Inc. Process for preparing microparticles having a low residual solvent volume
US20090169622A1 (en) * 2007-12-27 2009-07-02 Roxane Laboratories, Inc. Delayed-release oral pharmaceutical composition for treatment of colonic disorders
US20090197780A1 (en) * 2008-02-01 2009-08-06 Weaver Jimmie D Ultrafine Grinding of Soft Materials
PT2271348T (pt) 2008-03-28 2018-04-16 Paratek Pharm Innc Formulação de comprimido oral de composto de tetraciclina
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
US8697098B2 (en) 2011-02-25 2014-04-15 South Dakota State University Polymer conjugated protein micelles
US9750812B2 (en) 2008-09-27 2017-09-05 Jina Pharmaceuticals, Inc. Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof
CN101390825B (zh) * 2008-10-01 2010-12-29 山东省眼科研究所 一种伏立康唑眼内释药系统
WO2010086989A1 (ja) * 2009-01-29 2010-08-05 日東電工株式会社 口腔内フィルム状基剤及び製剤
EP2403500A4 (en) * 2009-03-05 2013-12-25 Genepharm India Private Ltd STABLE OLANZAPINE TABLETS AND PROCESS FOR PREPARING THE SAME
US20120160944A1 (en) * 2009-04-24 2012-06-28 Aaron Dodd Method for the production of commercial nanoparticle and micro particle powders
KR101743847B1 (ko) 2009-04-24 2017-06-05 아이슈티카 피티와이 리미티드 신규 인도메타신 제제
NZ722319A (en) * 2009-04-24 2018-01-26 Iceutica Pty Ltd A novel formulation of meloxicam
US8859003B2 (en) * 2009-06-05 2014-10-14 Intercontinental Great Brands Llc Preparation of an enteric release system
US20100307542A1 (en) * 2009-06-05 2010-12-09 Kraft Foods Global Brands Llc Method of Reducing Surface Oil on Encapsulated Material
US20100310726A1 (en) * 2009-06-05 2010-12-09 Kraft Foods Global Brands Llc Novel Preparation of an Enteric Release System
US9968564B2 (en) 2009-06-05 2018-05-15 Intercontinental Great Brands Llc Delivery of functional compounds
WO2010144865A2 (en) * 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
WO2010150144A2 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Low dose pharmaceutical compositions of celecoxib
ES2560210T3 (es) 2009-07-22 2016-02-17 Grünenthal GmbH Forma de dosificación resistente a la manipulación para opiádes sensibles a la oxidación
DE102009045116A1 (de) * 2009-09-29 2011-03-31 Evonik Degussa Gmbh Niederdruckvermahlungsverfahren
PT2525815E (pt) * 2010-01-24 2015-03-05 Novartis Ag Micropartículas de polímero biodegradável irradiadas
JP5588688B2 (ja) * 2010-01-28 2014-09-10 日東電工株式会社 フィルム状製剤
US20120322884A1 (en) * 2010-03-01 2012-12-20 University Of Manitoba Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
JP5751868B2 (ja) 2010-03-30 2015-07-22 日東電工株式会社 フィルム状製剤及びその製造方法
PT105116B (pt) 2010-05-14 2012-10-16 Hovione Farmaciencia S A Novas partículas de tetraciclina e agente protector.
CN101987082B (zh) * 2010-07-16 2013-04-03 钟术光 固体制剂及其制备方法
RU2604676C2 (ru) 2010-09-02 2016-12-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль
CN103402497A (zh) * 2010-12-02 2013-11-20 阿普塔利斯医药科技公司 快速分散颗粒、口腔崩解片以及方法
AU2012204462A1 (en) 2011-01-05 2013-07-11 Hospira, Inc. Spray drying vancomycin
CA2828253C (en) 2011-02-25 2016-10-18 South Dakota State University Polymer conjugated protein micelles
JP6063379B2 (ja) * 2011-04-22 2017-01-18 アステラス製薬株式会社 固形医薬組成物
WO2013017234A1 (en) 2011-07-29 2013-02-07 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
AR087359A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco
PL2782584T3 (pl) 2011-11-23 2021-12-13 Therapeuticsmd, Inc. Naturalne skojarzone hormonalne formulacje i terapie zastępcze
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2013091006A1 (en) * 2011-12-23 2013-06-27 Monash University Process for dry powder blending
JP5841433B2 (ja) 2012-01-11 2016-01-13 日東電工株式会社 口腔内フィルム状基剤及び製剤
FR2987266B1 (fr) 2012-02-28 2014-12-19 Debregeas Et Associes Pharma Procede d'obtention d'une composition pharmaceutique a base de modafinil, composition pharmaceutique ainsi obtenue et son application
WO2013151727A1 (en) * 2012-04-03 2013-10-10 Smith Medical Asd, Inc. Heparin-bulking agent compositions and methods thereof
ES2692944T3 (es) 2012-04-18 2018-12-05 Grünenthal GmbH Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis
US10039285B2 (en) * 2012-05-02 2018-08-07 Brigham Young University Ceragenin particulate materials and methods for making same
EP2861224A4 (en) 2012-06-15 2015-11-18 Univ Nova Southeastern EPINHEPHRINE NANOPARTICLES, PROCESS FOR THEIR MANUFACTURE AND METHODS OF USE THEREOF FOR THE TREATMENT OF EPINEPHRINE-RESPONSIBLE DISORDERS
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20140000297A1 (en) * 2012-06-29 2014-01-02 Air Liquide Industrial U.S. L.P. Production of Particles from Liquids or Suspensions with Liquid Cryogens
US8859005B2 (en) 2012-12-03 2014-10-14 Intercontinental Great Brands Llc Enteric delivery of functional ingredients suitable for hot comestible applications
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
CN105188679B (zh) 2013-03-15 2018-10-16 珍珠治疗公司 用于微粒晶体材料的状态调节的方法和系统
HUE055773T2 (hu) 2013-03-22 2021-12-28 Univ Nova Southeastern Epinefrin finom részecskék és módszerek azok alkalmazására az epinefrinre reagáló állapotok kezelésében
EA032465B1 (ru) 2013-07-12 2019-05-31 Грюненталь Гмбх Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления
WO2015078891A1 (en) * 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
KR101864465B1 (ko) 2014-01-21 2018-06-04 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 의료용 도관을 통한 생체 내 투여성 마이크로 입자
JP6572244B2 (ja) * 2014-02-25 2019-09-04 オービス バイオサイエンシズ， インク．Ｏｒｂｉｓ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 味覚マスキング薬製剤
PT107568B (pt) 2014-03-31 2018-11-05 Hovione Farm S A Processo de secagem por atomização para a produção de pós com propriedades melhoradas.
TWI601542B (zh) 2014-04-18 2017-10-11 林信湧 一種用於治療肺癌之吸入式醫藥組成物及其備製方法
TWI594772B (zh) 2014-04-18 2017-08-11 林信湧 一種用於治療高血壓之吸入式醫藥組成物及其備製方法
CN104606139B (zh) * 2014-05-16 2018-01-09 沈阳药科大学 一种药物粉末的制备与应用
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US11191853B2 (en) * 2014-08-15 2021-12-07 The Johns Hopkins University Post-surgical imaging marker
US10532041B2 (en) 2014-09-09 2020-01-14 Vectura Limited Formulation comprising glycopyrrolate, method and apparatus
CN105582683B (zh) * 2014-10-21 2019-01-18 中国科学院上海药物研究所 动态监控的高频超声雾化微粒制备系统
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
CN105815771B (zh) * 2016-03-18 2019-04-09 浙江工业大学 一种猴头菌素/plga微球的制备方法
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
ES2674808B1 (es) * 2016-12-30 2019-04-11 Bioinicia S L Instalacion y procedimiento de encapsulado industrial de sustanciastermolabiles
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
GB201716716D0 (en) 2017-10-12 2017-11-29 Univ Of Hertfordshire Higher Education Corporation Method for coating particles
CN108175763B (zh) * 2017-12-19 2020-09-11 亿腾医药（苏州）有限公司 一种布地奈德无菌原料及其吸入用混悬液的制备方法
CN108186581B (zh) * 2018-02-11 2021-08-31 海南锦瑞制药有限公司 一种伏立康唑制剂及其制备方法
CN110882222B (zh) * 2019-12-05 2021-12-03 北京博恩特药业有限公司 颗粒组合物及制备方法和应用
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN112587505A (zh) * 2020-10-16 2021-04-02 长春斯菲尔生物科技有限公司 一种奥氮平双羟萘酸盐缓释微粒制剂及其制备方法
CN112402381B (zh) * 2020-11-19 2023-02-28 广州一品红制药有限公司 一种盐酸克林霉素棕榈酸酯颗粒组合物及其制备方法
CN112535674B (zh) * 2020-12-25 2022-09-27 北京悦康科创医药科技股份有限公司 一种来曲唑片及其制备方法
CN114983945B (zh) * 2022-05-12 2024-03-26 温州医科大学附属第一医院 负载甘草酸铵的微球及其医疗用途
CN115096050B (zh) * 2022-07-07 2024-03-22 华北制药河北华民药业有限责任公司 一种头孢呋辛酯气相萃取干燥方法
CN115177965B (zh) * 2022-07-11 2023-04-25 西安国康瑞金制药有限公司 一种从黄体酮生产母液中回收黄体酮的系统和方法
CN115381799B (zh) * 2022-09-26 2023-11-03 苏州易合医药有限公司 一种涡旋混合制备阿莫西林吸入用球状颗粒的方法

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897010A (en) * 1971-07-02 1975-07-29 Linde Ag Method of and apparatus for the milling of granular materials
US3899144A (en) * 1974-07-22 1975-08-12 Us Navy Powder contrail generation
DE3702787A1 (de) * 1987-01-30 1988-08-11 Bayer Ag Verfahren und vorrichtung zum mikronisieren von feststoffen in strahlmuehlen
US4979384A (en) * 1987-09-23 1990-12-25 Lectron Products, Inc. Trunk lid lock with remote release
US4971805A (en) * 1987-12-23 1990-11-20 Teysan Pharmaceuticals Co., Ltd. Slow-releasing granules and long acting mixed granules comprising the same
DE3825469A1 (de) * 1988-07-27 1990-02-01 Basf Ag Verfahren zur dispergierung, zerkleinerung bzw. desagglomeration und sichtung von feststoffen
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
GB9106686D0 (en) * 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
US5205290A (en) * 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
GB9107628D0 (en) * 1991-04-10 1991-05-29 Moonbrook Limited Preparation of diagnostic agents
CA2079509C (en) * 1991-10-01 2002-05-14 Shigeyuki Takada Prolonged release microparticle preparation and production of the same
DE4140689B4 (de) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
US5186166A (en) * 1992-03-04 1993-02-16 Riggs John H Powder nebulizer apparatus and method of nebulization
GB9221329D0 (en) * 1992-10-10 1992-11-25 Delta Biotechnology Ltd Preparation of further diagnostic agents
KR100333115B1 (ko) * 1992-11-17 2002-12-02 미츠비시 파마 코포레이션 항정신병약함유서방성마이크로스피어및이의제조방법
DE4319990A1 (de) * 1993-06-17 1994-12-22 Messer Griesheim Gmbh Verfahren zum Herstellen von Teilchen aus Kunststoffen
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
AU694135B2 (en) * 1993-07-30 1998-07-16 Imcor Pharmaceutical Company Stabilized microbubble compositions for ultrasound
US5667927A (en) * 1993-08-30 1997-09-16 Shimadu Corporation Toner for electrophotography and process for the production thereof
GB9322014D0 (en) * 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
EP0759939B1 (en) * 1994-05-18 2005-07-20 Nektar Therapeutics Methods and compositions for the dry powder formulation of interferons
US5596815A (en) * 1994-06-02 1997-01-28 Jet-Pro Company, Inc. Material drying process
US6165976A (en) * 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
GB9423419D0 (en) * 1994-11-19 1995-01-11 Andaris Ltd Preparation of hollow microcapsules
PL321094A1 (en) * 1994-12-22 1997-11-24 Astra Ab Parathyroid hormone (pth) containing preparation administered by inhalation
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
US6045913A (en) * 1995-11-01 2000-04-04 Minnesota Mining And Manufacturing Company At least partly fused particulates and methods of making them by flame fusion
US6254981B1 (en) * 1995-11-02 2001-07-03 Minnesota Mining & Manufacturing Company Fused glassy particulates obtained by flame fusion
AU721209B2 (en) * 1996-03-05 2000-06-29 Acusphere, Inc. Microencapsulated fluorinated gases for use as imaging agents
US5611344A (en) * 1996-03-05 1997-03-18 Acusphere, Inc. Microencapsulated fluorinated gases for use as imaging agents
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6017310A (en) * 1996-09-07 2000-01-25 Andaris Limited Use of hollow microcapsules
WO1998015263A2 (en) * 1996-10-09 1998-04-16 Takeda Chemical Industries, Ltd. A method for producing a microparticle
US6068600A (en) * 1996-12-06 2000-05-30 Quadrant Healthcare (Uk) Limited Use of hollow microcapsules
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6051257A (en) * 1997-02-24 2000-04-18 Superior Micropowders, Llc Powder batch of pharmaceutically-active particles and methods for making same
DE19728382C2 (de) * 1997-07-03 2003-03-13 Hosokawa Alpine Ag & Co Verfahren und Vorrichtung zur Fließbett-Strahlmahlung
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
US6187345B1 (en) * 1998-04-14 2001-02-13 Jack Lawrence James Flutamide compositions and preparations
WO1999053901A1 (en) * 1998-04-18 1999-10-28 Glaxo Group Limited Pharmaceutical aerosol formulation
US6423345B2 (en) * 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
US6451349B1 (en) * 1998-08-19 2002-09-17 Quadrant Healthcare (Uk) Limited Spray-drying process for the preparation of microparticles
CA2350531A1 (en) * 1998-11-13 2000-05-25 Smriti Iyengar Method for treating pain
US6560897B2 (en) * 1999-05-03 2003-05-13 Acusphere, Inc. Spray drying apparatus and methods of use
US6223455B1 (en) * 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
US6610317B2 (en) * 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6443376B1 (en) * 1999-12-15 2002-09-03 Hosokawa Micron Powder Systems Apparatus for pulverizing and drying particulate matter
EP1129705A1 (en) * 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Powder formulation for inhalation
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
US6589557B2 (en) * 2000-06-15 2003-07-08 Acusphere, Inc. Porous celecoxib matrices and methods of manufacture thereof
US6800297B2 (en) * 2000-06-15 2004-10-05 Acusphere, Inc. Porous COX-2 inhibitor matrices and methods of manufacture thereof
US6859557B1 (en) * 2000-07-07 2005-02-22 Microsoft Corp. System and method for selective decoding and decompression
US6797342B1 (en) * 2000-09-15 2004-09-28 Xerox Corporation Deflocculation apparatus and methods thereof
NZ525231A (en) * 2000-09-20 2004-08-27 Skyepharma Canada Inc Phospholipid stabilised feno-fibrate microparticles for pharmaceutical use
US6878751B1 (en) * 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
DK1920763T3 (da) * 2000-11-30 2014-07-07 Vectura Ltd Farrmaceutiske præparater til inhalation
WO2002043701A2 (en) * 2000-11-30 2002-06-06 Vectura Limited Method of making particles for use in a pharmaceutical composition
WO2002043693A2 (en) * 2000-11-30 2002-06-06 Vectura Limited Pharmaceutical compositions for inhalation
DE60140268D1 (de) * 2000-11-30 2009-12-03 Vectura Ltd Partikel zur verwendung in einer pharmazeutischen zusammensetzung
DE10061932A1 (de) * 2000-12-13 2002-10-24 Pharmatech Gmbh Wirkstoffhaltige Mikropartikel und Verfahren zur Herstellung der Mikropartikel durch Abrasion
JP2004516304A (ja) * 2000-12-22 2004-06-03 アスペン・エアロジエルズ・インコーポレーテツド エーロゲル粉末含有治療剤
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
WO2002080774A2 (en) * 2001-04-06 2002-10-17 Bracco Research S.A. Method for improved measurement of local physical parameters in afluid-filled cavity
US20030008014A1 (en) * 2001-06-20 2003-01-09 Shelness Gregory S. Truncated apolipoprotein B-containing lipoprotein particles for delivery of compounds to tissues or cells
US6681768B2 (en) * 2001-06-22 2004-01-27 Sofotec Gmbh & Co. Kg Powder formulation disintegrating system and method for dry powder inhalers
AU2002364508A1 (en) * 2001-11-21 2003-06-10 Alexza Molecular Delivery Corporation Open-celled substrates for drug delivery
US6756381B2 (en) * 2002-02-21 2004-06-29 Supergen, Inc. Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof
DE10214031A1 (de) * 2002-03-27 2004-02-19 Pharmatech Gmbh Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation
US8501232B2 (en) * 2002-04-23 2013-08-06 Nanotherapeutics, Inc. Process of forming and modifying particles and compositions produced thereby
US6919068B2 (en) * 2002-05-17 2005-07-19 Point Biomedical Corporation Method of preparing gas-filled polymer matrix microparticles useful for echographic imaging
US20040045546A1 (en) * 2002-09-05 2004-03-11 Peirce Management, Llc Pharmaceutical delivery system for oral inhalation through nebulization consisting of inert substrate impregnated with substance (S) to be solubilized or suspended prior to use
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US7511079B2 (en) * 2003-03-24 2009-03-31 Baxter International Inc. Methods and apparatuses for the comminution and stabilization of small particles
JP4233936B2 (ja) * 2003-06-23 2009-03-04 本田技研工業株式会社 エンジンの始動装置
US7485283B2 (en) * 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging

Also Published As

Publication number Publication date
AU2003295698A1 (en) 2004-07-29
ZA200504213B (en) 2006-02-22
CA2511313A1 (en) 2004-07-22
WO2004060344A3 (en) 2004-12-02
US20040121003A1 (en) 2004-06-24
WO2004060344A2 (en) 2004-07-22
RU2005122656A (ru) 2006-01-20
EP1575560A2 (en) 2005-09-21
US20050079138A1 (en) 2005-04-14
CN1726009A (zh) 2006-01-25
US20060093677A1 (en) 2006-05-04
US20060093678A1 (en) 2006-05-04
KR20050088201A (ko) 2005-09-02
JP2006514044A (ja) 2006-04-27

Similar Documents

Publication Publication Date Title
BR0317611A (pt) Métodos para produção de formulações farmacêuticas que compreendem micropartìculas aglomeradas
BR0003158A (pt) Formulação de dosagem oral de derretimentoinstantâneo
US3981996A (en) Pharmaceutical skin compositions
BR0311908A (pt) Composição farmacêutica para liberação controlada de substâncias ativas e seu método de fabricação
MX171463B (es) Sistema de dosificacion de liberacion sostenida y procedimiento para su preparacion
BR9810125A (pt) Composição de polìmero aromático de monivinilideno modificado com borracha e seu processo de produção
AR015491A1 (es) Composicion medicamentosa bajo la forma de pellets blando y procedimientos para prepararlos e inhaladores que incluyen dicha composicion.
BR0303348A (pt) Formulações de aerossol para administração pulmonar de medicamentos com o intuito de produzir efeito sistêmico
BR0214280A (pt) Composição farmacêuticas em forma particulada
BRPI0709847B8 (pt) composição farmacêutica sólida de liberação rápida contendo paracetamol e carbonato de cálcio
MX2007003162A (es) Composicion farmaceutica que comprende una dispersion solida con una matriz polimerica que comprende una fase continua de polidextrosa y una fase continua de un polimero distinto de la polidextrosa.
BR9908771A (pt) Processos para a liberação de um agente ativo e de insulina para os pulmões de um paciente humano, dispositivo para aumentar a biodisponibilidade de um agente ativo, e, dispositivos para a liberação de um agente ativo e de insulina para os pulmões de um paciente humano
BRPI0116945B8 (pt) preparado para tratamento local de epitélio hiperproliferativo
BR0111001A (pt) Produção contìnua de granulação farmacêutica
CA2347856A1 (en) Dry powder for inhalation
HRP20100674T1 (hr) Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka
BRPI1001318B1 (pt) Artigos moldados liofilizados e método para produzir um artigomoldado liofilizado
ES2175073T3 (es) Procedimiento de preparacion de formas para la administracion oral de antibioticos beta-lactamicos de rapida dispersabilidad en agua.
Tobyn et al. Prediction of physical properties of a novel polysaccharide controlled release system. I
BR0012258A (pt) Processo para a preparação de preparados farmacêuticos sólidos, que se decompõem rapidamente
BR0214706A (pt) Estrutura absorvente envolta
BRPI1001317A2 (pt) artigo moldado secado por congelamento contendo fosfato de ascorbila de magnésio
AR018607A1 (es) Preparacion farmaceutica que en calidad de ingrediente activo contiene levotiroxina sodica, y un procedimiento para su preparacion
MXPA06000243A (es) Formulacion farmaceutica liofilizada estable de tetrodotoxina.
AR024564A1 (es) Composicion que comprende esfingomielinasa para el uso como una preparacion dietetica, suplemento dietario o producto farmaceutico

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2162 DE 12/06/2012 E CONSIDERANDO A AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE.